Statin Use is Associated With Insulin Resistance in Participants of the Canadian Multicentre Osteoporosis Study

Abstract Context Statins have been linked to the development of diabetes and atherosclerotic plaque calcification in patients with cardiac disease. Objective To determine the association between statin use and statin characteristics and insulin resistance and abdominal aortic calcification (AAC) in participants of the Canadian Multicentre Osteoporosis Study (CaMos). Design Observational study. Setting General community. Participants Nondiabetic participants of the Kingston CaMos site Intervention Insulin resistance and AAC in statin users and nonstatin users were compared with and without the inclusion of a propensity score (PS) to be on a statin. The covariates of hypertension, sex, body mass index, smoking, kidney stones, and age that were included in the PS were selected based on clinical judgment confirmed by the statistical analysis of a difference between statin users and nonstatin users. Main Outcome Measures Insulin resistance measured by the homeostasis model assessment (HOMA-IR) and AAC assessed on lateral spine radiographs using the Framingham methodology. Results Using a general linear model, statin use was associated with higher levels of HOMA-IR after stratified PS adjustment (β = 1.52, [1.18–1.95], P < 0.01). Hydrophilic statin users (n = 9) and lipophilic statins users (n = 30) had higher HOMA-IR compared to nonstatin users (n = 125) ([β = 2.29, (1.43–3.68), P < 0.001] and [β = 1.36, (1.04–1.78), P < 0.05]), respectively, in general linear models after stratified PS adjustment. Statin use was associated with AAC without stratifying by PS in the Wilcoxon test, but was no longer significant when stratified by PS. Conclusions Statins, widely prescribed drugs to lower cholesterol, may have unintended consequences related to glucose homeostasis that could be relevant in healthy aging.

[1]  Jie Luo,et al.  Endogenous sterol intermediates of the mevalonate pathway regulate HMGCR degradation and SREBP-2 processing[S] , 2019, Journal of Lipid Research.

[2]  A. B. Kuhlman,et al.  Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women: the LIFESTAT study. , 2019, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[3]  T. Matsunaga,et al.  [Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia]. , 2019, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[4]  H. Shirakawa,et al.  Menaquinone-4 Amplified Glucose-Stimulated Insulin Secretion in Isolated Mouse Pancreatic Islets and INS-1 Rat Insulinoma Cells , 2019, International journal of molecular sciences.

[5]  O. Bourron,et al.  Vitamin K: a nutrient which plays a little-known role in glucose metabolism , 2019, Current opinion in clinical nutrition and metabolic care.

[6]  A. B. Kuhlman,et al.  Glucose homeostasis in statin users—The LIFESTAT study , 2018, Diabetes/metabolism research and reviews.

[7]  Xueyan Fu,et al.  Atorvastatin Decreases Renal Menaquinone-4 Formation in C57BL/6 Male Mice. , 2019, The Journal of nutrition.

[8]  T. Eleftheriadis,et al.  Association of the Inactive Circulating Matrix Gla Protein with Vitamin K Intake, Calcification, Mortality, and Cardiovascular Disease: A Review , 2019, International journal of molecular sciences.

[9]  C. Zheng,et al.  Emerging Role of Vitamins D and K in Modulating Uremic Vascular Calcification: The Aspect of Passive Calcification , 2019, Nutrients.

[10]  Nan Zhang,et al.  Identification of Fatty Acid Desaturase 6 in Golden Pompano Trachinotus Ovatus (Linnaeus 1758) and Its Regulation by the PPARαb Transcription Factor , 2018, International journal of molecular sciences.

[11]  B. Chogtu,et al.  Analysis of glycemic status in diabetes-naïve patients on statins: A hospital-based cross-sectional study , 2018, Indian journal of pharmacology.

[12]  N. Toussaint,et al.  Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis , 2018, Seminars in dialysis.

[13]  B. Yeap,et al.  Undercarboxylated Osteocalcin: Experimental and Human Evidence for a Role in Glucose Homeostasis and Muscle Regulation of Insulin Sensitivity , 2018, Nutrients.

[14]  Sang Min Park,et al.  The effect of change in fasting glucose on the risk of myocardial infarction, stroke, and all-cause mortality: a nationwide cohort study , 2018, Cardiovascular Diabetology.

[15]  Joana Real,et al.  Lipophilicity predicts the ability of nonsulphonylurea drugs to block pancreatic beta‐cell KATP channels and stimulate insulin secretion; statins as a test case , 2018, Endocrinology, diabetes & metabolism.

[16]  D. M. Abd El Motteleb,et al.  Vitamin K2 alleviates type 2 diabetes in rats by induction of osteocalcin gene expression. , 2018, Nutrition.

[17]  M. Volpe,et al.  Patient at intermediate cardiovascular risk: statins, yes! - antihypertensive therapy, maybe. , 2018, Journal of cardiovascular medicine.

[18]  P. Sil,et al.  Vitamin K1 inversely correlates with glycemia and insulin resistance in patients with type 2 diabetes (T2D) and positively regulates SIRT1/AMPK pathway of glucose metabolism in liver of T2D mice and hepatocytes cultured in high glucose. , 2018, The Journal of nutritional biochemistry.

[19]  Shuzhuang Li,et al.  Effect of vitamin K2 on type 2 diabetes mellitus: A review. , 2018, Diabetes research and clinical practice.

[20]  H. Martino,et al.  Effect of vitamin K in bone metabolism and vascular calcification: A review of mechanisms of action and evidences , 2017, Critical reviews in food science and nutrition.

[21]  L. Schurgers,et al.  Does statins promote vascular calcification in chronic kidney disease? , 2017, European journal of clinical investigation.

[22]  J. Knowles,et al.  Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials). , 2016, The American journal of cardiology.

[23]  M. Blettner,et al.  Propensity Score: an Alternative Method of Analyzing Treatment Effects. , 2016, Deutsches Arzteblatt international.

[24]  Laura V Minard,et al.  Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis , 2016, PloS one.

[25]  Jacques P. Brown,et al.  Dietary patterns in men and women are simultaneously determinants of altered glucose metabolism and bone metabolism. , 2016, Nutrition research.

[26]  D. Manuel,et al.  Comparing Guidelines for Statin Treatment in Canada and the United States , 2015, Journal of the American Heart Association.

[27]  K. Nakagawa,et al.  Functional Characterization of the Vitamin K2 Biosynthetic Enzyme UBIAD1 , 2015, PloS one.

[28]  Yu Kataoka,et al.  Impact of statins on serial coronary calcification during atheroma progression and regression. , 2015, Journal of the American College of Cardiology.

[29]  C. Mantzoros,et al.  Statin treatment and new-onset diabetes: a review of proposed mechanisms. , 2014, Metabolism: clinical and experimental.

[30]  Michael E. Miller,et al.  Association between circulating vitamin K1 and coronary calcium progression in community-dwelling adults: the Multi-Ethnic Study of Atherosclerosis. , 2013, The American journal of clinical nutrition.

[31]  L. Bujanda,et al.  Several statins increase body and liver fat accumulation in a model of metabolic syndrome. , 2013, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[32]  S. de Servi,et al.  Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. , 2013, The American journal of cardiology.

[33]  C. Mandarim-de-Lacerda,et al.  Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. , 2012, Clinical science.

[34]  P. Barter,et al.  Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. , 2011, Journal of the American College of Cardiology.

[35]  M. Hamilton,et al.  Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. , 2009, Endocrinology.

[36]  Mika Kivimäki,et al.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study , 2009, The Lancet.

[37]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[38]  L. Schurgers,et al.  Matrix Gla-protein: The calcification inhibitor in need of vitamin K , 2008, Thrombosis and Haemostasis.

[39]  A. Gotto,et al.  Anti‐adipogenic action of pitavastatin occurs through the coordinate regulation of PPARγ and Pref‐1 expression , 2007 .

[40]  L. Badimón,et al.  Influence of statin use on endothelial function: from bench to clinics. , 2007, Current pharmaceutical design.

[41]  M. Nakata,et al.  Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control , 2006, Diabetologia.

[42]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[43]  L. Schurgers,et al.  Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. , 2001, Biochemical and biophysical research communications.

[44]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[45]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[46]  D. Kiel,et al.  New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. , 1997, Atherosclerosis.

[47]  Jacques P. Brown,et al.  Research Notes: The Canadian Multicentre Osteoporosis Study (CaMos): Background, Rationale, Methods , 1999, Canadian Journal on Aging / La Revue canadienne du vieillissement.

[48]  C. J. Blankley,et al.  Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase. , 1991, Journal of medicinal chemistry.